IFNB1

Summary

Gene Symbol: IFNB1
Description: interferon beta 1
Alias: IFB, IFF, IFN-beta, IFNB, interferon beta, fibroblast interferon, interferon, beta 1, fibroblast, interferon-beta
Species: human

Top Publications

  1. pmc The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses
    Xiaobo Lei
    State Key Laboratory of Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, People s Republic of China
    J Virol 84:8051-61. 2010
  2. pmc Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages
    Lisa Nowoslawski Akhtar
    Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Immunol 185:2393-404. 2010
  3. pmc Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells
    Zhaoduan Liang
    Department of Immunology, Institute of Immunology, Institute of Human Virology, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou, China
    PLoS ONE 6:e23346. 2011
  4. pmc Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter
    Nathalie Cloutier
    Laboratory of Virology, Rheumatology and Immunology Research Center, Centre Hospitalier Universitaire de Quebec Research Center and Faculty of Medicine, Laval University, Quebec City, Quebec G1V 4G2, Canada
    J Biol Chem 285:7208-21. 2010
  5. pmc Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon
    Manish Kumar
    Department of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Virol 85:987-95. 2011
  6. pmc A novel IFN regulatory factor 3-dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts
    Anne Danielle C Chessler
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
    J Immunol 181:7917-24. 2008
  7. doi Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF)3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells
    Claudia Buss
    Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Immunol 184:3072-8. 2010
  8. pmc Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1
    Atsushi Iwai
    Department of Bioresources, hHokkaido University Research Center for Zoonosis Control, North 20, West 10 Kita ku, Sapporo, Hokkaido 001 0020, Japan
    J Biol Chem 285:32064-74. 2010
  9. ncbi Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3
    Susan E Sweeney
    University of California San Diego, School of Medicine, La Jolla, CA 92093, USA
    Arthritis Rheum 56:743-52. 2007
  10. pmc Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression
    Sylvain Lefort
    Rheumatology and Immunology Research Center, Room T1 49, 2705 Laurier Blvd, Quebec, Quebec G1V 4G2, Canada
    J Virol 81:10950-60. 2007

Research Grants

  1. Molecular Stratification of Multiple Sclerosis and Associated Neuro-autoimmune Di
    Robert C Axtell; Fiscal Year: 2012
  2. Robert C Axtell; Fiscal Year: 2015
  3. Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)
    Fred D Lublin; Fiscal Year: 2012
  4. IFN-BETA CONTROL OF TH CELL DIFFERENTIATION/FUNCTION
    GIJSBERT VAN SEVENTER; Fiscal Year: 2003
  5. Methamphetamine, Stress and SIV: Effects at Blood-Brain Barrier and Lymph Nodes
    John P Capitanio; Fiscal Year: 2010
  6. Ratna B Ray; Fiscal Year: 2016
  7. Visualizing Interferon-beta Induction In Vivo
    Joan Durbin; Fiscal Year: 2009
  8. ERIC KIRK LAU; Fiscal Year: 2014
  9. ATF3-Mediated Transcriptional Repression of Interferon-beta
    STEVE LEE WEINSTEIN; Fiscal Year: 2010
  10. Bone Marrow Stem Cells: Novel Treatment of Human Glioma
    Frederick F Lang; Fiscal Year: 2010

Detail Information

Publications347 found, 100 shown here

  1. pmc The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses
    Xiaobo Lei
    State Key Laboratory of Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, People s Republic of China
    J Virol 84:8051-61. 2010
    ..Together, these results suggest that inhibition of RIG-I-mediated type I IFN responses by the 3C protein may contribute to the pathogenesis of EV71 infection...
  2. pmc Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages
    Lisa Nowoslawski Akhtar
    Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Immunol 185:2393-404. 2010
    ....
  3. pmc Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells
    Zhaoduan Liang
    Department of Immunology, Institute of Immunology, Institute of Human Virology, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou, China
    PLoS ONE 6:e23346. 2011
    ....
  4. pmc Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter
    Nathalie Cloutier
    Laboratory of Virology, Rheumatology and Immunology Research Center, Centre Hospitalier Universitaire de Quebec Research Center and Faculty of Medicine, Laval University, Quebec City, Quebec G1V 4G2, Canada
    J Biol Chem 285:7208-21. 2010
    ..IFN-beta transcription and synthesis by competing with the binding of interferon regulatory factor-3 (IRF3) to the IFNB promoter...
  5. pmc Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon
    Manish Kumar
    Department of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Virol 85:987-95. 2011
    ..Hepatitis B virus now joins hepatitis C virus and hepatitis A virus in targeting the same innate immune response pathway, presumably as a shared strategy to benefit replication of these viruses in the liver...
  6. pmc A novel IFN regulatory factor 3-dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts
    Anne Danielle C Chessler
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
    J Immunol 181:7917-24. 2008
    ..Together, these findings identify the existence of a novel TLR-independent pathogen-sensing mechanism in immune and nonimmune cells that converges on TBK1 and IFN regulatory factor 3 for activation of IFN-beta gene expression...
  7. doi Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF)3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells
    Claudia Buss
    Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Immunol 184:3072-8. 2010
    ..In conclusion, C. pneumoniae infection of endothelial cells activates an MAVS-, IRF3-, and IRF7-dependent signaling, which controls bacterial growth and might modulate development of vascular lesions...
  8. pmc Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1
    Atsushi Iwai
    Department of Bioresources, hHokkaido University Research Center for Zoonosis Control, North 20, West 10 Kita ku, Sapporo, Hokkaido 001 0020, Japan
    J Biol Chem 285:32064-74. 2010
    ..These findings demonstrate that the viral polymerase plays an important role for regulating host anti-viral response through the binding to IPS-1 and inhibition of IFNβ production...
  9. ncbi Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3
    Susan E Sweeney
    University of California San Diego, School of Medicine, La Jolla, CA 92093, USA
    Arthritis Rheum 56:743-52. 2007
    ..This study was designed to investigate the role of the IKK-related kinase IKKepsilon and IFN regulatory factor 3 (IRF-3) in the activation of antiviral genes in rheumatoid arthritis (RA)...
  10. pmc Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression
    Sylvain Lefort
    Rheumatology and Immunology Research Center, Room T1 49, 2705 Laurier Blvd, Quebec, Quebec G1V 4G2, Canada
    J Virol 81:10950-60. 2007
    ..A new role for K-bZIP as a protein involved in immune evasion is therefore uncovered...
  11. doi The major outer membrane protein of a periodontopathogen induces IFN-beta and IFN-stimulated genes in monocytes via lipid raft and TANK-binding kinase 1/IFN regulatory factor-3
    Sung Hoon Lee
    Department of Oral Microbiology and Immunology, Seoul National University, Seoul, Republic of Korea
    J Immunol 182:5823-35. 2009
    ..Our results demonstrate that MspTL, the major outer protein of T. lecithinolyticum, induced IFN-beta expression and subsequent up-regulation of IP-10 and RANTES via TBK1/IRF-3/STAT-1 signaling secondary to lipid raft activation...
  12. doi The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma
    Masasuke Ohno
    Department of Neurosurgery, Aichi Cancer Center Research Institute, Nagoya 466 8550, Japan
    Mol Cancer Res 7:2022-30. 2009
    ..These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis...
  13. doi Toll-like receptor-3 ligation-induced indoleamine 2, 3-dioxygenase expression in human trophoblasts
    Bo Wang
    Department of Obstetrics and Gynecology, University of Tokyo, 7 3 1 Hongo Bunkyo Tokyo, 113 8655, Japan
    Endocrinology 152:4984-92. 2011
    ..These findings suggest that upon viral infection, trophoblasts induce IDO and in turn contribute to antimicrobial activity and maintenance of fetomaternal tolerance...
  14. ncbi Interferon induction by HIV-1-infected cells: a possible role of sulfatides or related glycolipids
    H Ankel
    Medical College of Wisconsin, Milwaukee 53226, USA
    Virology 221:113-9. 1996
    ..A partial homology of an epitope on the V3 loop of gp 120 with a previously suggested binding domain for sulfated glycoconjugates supports this conclusion...
  15. doi 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression
    Sadaoki Sakai
    Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo 160 8582, Japan
    J Bone Miner Metab 27:643-52. 2009
    ..Thus, our study may provide a molecular basis for the treatment of human bone diseases by 1alpha,25(OH)(2)D(3) through regulation of the IFN-beta and NFATc1 axis...
  16. pmc Enhancement of anti-Aspergillus T helper type 1 response by interferon-β-conditioned dendritic cells
    Valerie Gafa
    Department of Infectious, Parasitic, Immuno Mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
    Immunology 131:282-8. 2010
    ....
  17. pmc Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction
    Hiroyuki Oshiumi
    Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    PLoS ONE 5:e14258. 2010
    ..The results enable us to conclude that HCV infection is promoted by modulating the dual function of DDX3...
  18. ncbi TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta
    Hiroyuki Oshiumi
    Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari ku, Osaka 537 8511, Japan
    J Biol Chem 278:49751-62. 2003
    ..This results in the construction of MyD88-dependent and -independent pathways separately downstream of the two distinct adapters...
  19. doi Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction
    Masashi Shingai
    Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita ku, Sapporo 060 8638, Japan
    Int Immunol 20:1169-80. 2008
    ....
  20. doi Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3
    Sabrina Marozin
    II Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Mol Ther 16:1789-97. 2008
    ..This work may provide a potential molecular basis for selecting HCC patients for oncolytic VSV therapy in future clinical trials...
  21. doi Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R
    Christiane A Opitz
    Department of Neurooncology, University Hospital of Heidelberg and German Cancer Research Center, Heidelberg, Germany
    Stem Cells 27:909-19. 2009
    ..PKR and IFN-beta play a central, previously unidentified role in orchestrating the production of immunosuppressive kynurenines by MSC...
  22. doi Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and
    Shiyan Yu
    Key Laboratory of Medical Molecular Virology, Ministry of Education and Public Health, Shanghai Medical College, Fudan University, Shanghai 200032, PR China
    J Gen Virol 91:2080-90. 2010
    ..Taken together, these findings reveal a novel role of HBV polymerase in HBV counteraction of IFN-beta production in human hepatocytes...
  23. pmc The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production
    Huizhi Wang
    Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY 40202, USA
    J Immunol 186:675-84. 2011
    ....
  24. pmc Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication
    S Gessani
    Department of Virology, Istituto Superiore di Sanita, Rome, Italy
    J Virol 68:1983-6. 1994
    ..These results indicate that (i) HIV-1 (possibly in part through its gp120 protein) induces low levels of IFN-beta in macrophages and (ii) this IFN-beta is very effective in inducing an antiviral state in differentiated macrophages...
  25. ncbi Induction of cytokines by HIV-1 and its gp120 protein in human peripheral blood monocyte/macrophages and modulation of cytokine response during differentiation
    S Gessani
    Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    J Leukoc Biol 62:49-53. 1997
    ....
  26. ncbi Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia
    C Aucan
    Wellcome Trust Centre for Human Genetics, Henry Wellcome Building of Genomic Medicine, Roosevelt Drive, Oxford, OX3 7BN, UK
    Genes Immun 4:275-82. 2003
    ..8, d.f.=2, P=0.002 and 3 x 2 chi(2)=15.2, d.f.=2, P=0.0005, respectively). These data suggest a role for the type I interferon pathway in resistance to cerebral malaria...
  27. pmc Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production
    Gregory T Melroe
    Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115, USA
    J Virol 78:8411-20. 2004
    ..These results argue that HSV-1 has multiple mechanisms to inhibit the production of IFN-beta, providing additional ways in which HSV-1 can block the IFN-mediated host response...
  28. ncbi Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection
    Bobbie Ann Austin
    Department of Ophthalmology, University of Oklahoma Health Sciences Center, Biomedical Sciences Building, 608 Stanton L Young Boulevard, Oklahoma City, OK 73104, USA
    J Immunol 175:1100-6. 2005
    ....
  29. ncbi Modulation of HIV-1 transcription by cytokines and chemokines
    K F T Copeland
    Molecular Medicine Program, Ottawa Health Research Institute, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada
    Mini Rev Med Chem 5:1093-101. 2005
    ..This review will examine the complexities of the positive and negative control of HIV transcription by cytokines and chemokines...
  30. ncbi Adrenergic inhibition of innate anti-viral response: PKA blockade of Type I interferon gene transcription mediates catecholamine support for HIV-1 replication
    Alicia Collado-Hidalgo
    Department of Psychiatry, David E Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1678, USA
    Brain Behav Immun 20:552-63. 2006
    ..This effect was specific to Type I interferons and driven by PKA-mediated repression of IFNA and IFNB gene transcription...
  31. ncbi Legionella pneumophila induces IFNbeta in lung epithelial cells via IPS-1 and IRF3, which also control bacterial replication
    Bastian Opitz
    Department of Internal Medicine Infectious Diseases and Pulmonary Medicine, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Biol Chem 281:36173-9. 2006
    ..pneumophila in lung epithelial cells. In conclusion, we demonstrated a critical role of IPS-1, IRF3, and IFNbeta in Legionella infection of lung epithelium...
  32. pmc The infected cell protein 0 encoded by bovine herpesvirus 1 (bICP0) induces degradation of interferon response factor 3 and, consequently, inhibits beta interferon promoter activity
    Kazima Saira
    Department of Veterinary and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska, Lincoln, NE 68503, USA
    J Virol 81:3077-86. 2007
    ..Collectively, these studies suggest that the ability of bICP0 to reduce IRF3 protein levels is important with respect to disarming the IFN response during productive infection...
  33. doi IFNbeta responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI)
    Juliane Lippmann
    Department of Internal Medicine Infectious Diseases and Pulmonary Medicine, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cell Microbiol 10:2579-88. 2008
    ..In conclusion, intracellular bacteria and cytosolic poly(dA-dT) activate IFNbeta responses in different human cells without requiring human ZBP1...
  34. pmc Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway
    Shin Ichi Yokota
    Department of Microbiology, Sapporo Medical University School of Medicine, South 1, West 17, Chuo Ku, Sapporo 060 8556, Hokkaido, Japan
    J Virol 78:6282-6. 2004
    ..In conclusion, the SOCS3 protein appears to be mainly responsible for the suppression of IFN signaling and IFN production that occurs during HSV-1 infection...
  35. ncbi Human interferons alpha, beta and omega
    Joseph Bekisz
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Growth Factors 22:243-51. 2004
    ..The interaction of IFN-alpha/beta with its receptor components results in the activation of a number of signaling pathways. The regulation of specific genes and proteins contributes to the numerous biological functions of Type I IFNs...
  36. ncbi Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes
    Kui Li
    Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas 77555 1019, USA
    J Biol Chem 280:16739-47. 2005
    ..We conclude that hepatocytes contain two distinct antiviral signaling pathways leading to expression of type I IFNs, one dependent upon TLR3 and the other dependent on RIG-I, with little cross-talk between these pathways...
  37. ncbi Sendai virus defective-interfering genomes and the activation of interferon-beta
    Laura Strahle
    Department of Microbiology and Molecular Medicine, University of Geneva School of Medicine, 11 Ave de Champel, CH1211 Geneva, Switzerland
    Virology 351:101-11. 2006
    ....
  38. pmc Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus
    Masaki Mibayashi
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 81:514-24. 2007
    ..Our results indicate that, in addition to sequestering dsRNA, the NS1 of influenza A virus binds to RIG-I and inhibits downstream activation of IRF-3, preventing the transcriptional induction of IFN-beta...
  39. ncbi NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction
    Miwa Sasai
    Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita ku, Sapporo 060 8638, Japan
    J Immunol 177:8676-83. 2006
    ..Both the cytoplasmic and TLR3-mediated dsRNA recognition pathways converge upon NAP1 for the activation of the IRF-3 and IFN-beta promoter...
  40. pmc In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the releas
    Giorgio Mangino
    Department of Biology University Roma Tre, Viale G Marconi 446, 00146 Rome, Italy
    J Virol 81:2777-91. 2007
    ..In addition, we have observed the activation of interferon regulatory factor 3, leading to the synthesis of beta interferon mRNA and protein, which in turn induces STAT2 phosphorylation. All of these effects require Nef myristoylation...
  41. ncbi Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-beta enhancer
    Carlos R Escalante
    Department of Structural and Chemical Biology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mol Cell 26:703-16. 2007
    ..Together, the structure and accompanying biological data provide insights into the assembly of the IFN-beta enhanceosome in mammals...
  42. pmc An atomic model of the interferon-beta enhanceosome
    Daniel Panne
    The Jack and Eileen Connors Structural Biology Laboratory, Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Howard Hughes Medical Institute, 250 Longwood Avenue, Boston, MA 02115, USA
    Cell 129:1111-23. 2007
    ..Contacts with virtually every nucleotide pair account for the evolutionary invariance of the enhancer sequence...
  43. pmc Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis
    Ronan J Walsh
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 56:3784-92. 2007
    ....
  44. pmc Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients
    Lisa G M van Baarsen
    Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, The Netherlands
    PLoS ONE 3:e1927. 2008
    ..Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy...
  45. pmc The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3
    Rowan Higgs
    Molecular and Cellular Therapeutics, Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
    J Immunol 181:1780-6. 2008
    ..Collectively, this demonstrates a novel role for Ro52 in turning off and thus limiting IRF3-dependent type I IFN production by targeting the transcription factor for polyubiquitination and subsequent proteasomal degradation...
  46. doi The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis
    Chris J Hedegaard
    Institute for Inflammation Research, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Clin Immunol 129:80-9. 2008
    ..However, the increase in proinflammatory IL-6 and the decrease in anti-inflammatory IL-10 responses suggest that IFN-beta has more diverse effects than previously assumed...
  47. doi Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection
    Hiroyuki Oshiumi
    Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    J Biol Chem 284:807-17. 2009
    ..We infer that a variety of RIG-I-ubiquitinating molecular complexes sustain RIG-I activation to modulate RNA virus replication in the cytoplasm...
  48. doi Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo
    Stefan Lienenklaus
    Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany
    J Immunol 183:3229-36. 2009
    ..This relatively high constitutive expression was controlled by the NF Aire and might influence induction of tolerance or T cell development...
  49. pmc Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction
    Lina Fan
    Center for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    J Virol 84:1785-91. 2010
    ....
  50. doi DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential
    Hiroyuki Oshiumi
    Department of Microbiology and Immunology, Hokkaido University Graduate School of Medicine, Kita ku, Sapporo, Japan
    Eur J Immunol 40:940-8. 2010
    ..Forced expression of DDX3 augmented virus-mediated IFN-beta induction and host cell protection against virus infection. Hence, DDX3 is an antiviral IPS-1 enhancer...
  51. pmc Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases
    Mark A Clementz
    Department of Microbiology and Immunology, Loyola University Medical Center, Bldg 105, Rm 3929, 2160 South First Avenue, Maywood, IL 60153, USA
    J Virol 84:4619-29. 2010
    ..Overall, these results demonstrate the multifunctional nature of the coronavirus PLP domain as a viral protease, DUB, and IFN antagonist and suggest that these independent activities may provide multiple targets for antiviral therapies...
  52. doi Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?
    D Hesse
    Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital, Rigshospitalet, Denmark
    Eur J Neurol 18:266-72. 2011
    ..We studied the relationship between a type I interferon-like response in untreated patients with MS and disease activity...
  53. doi B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis
    Vinod S Ramgolam
    Department of Neurology, University of North Carolina, Chapel Hill, NC 27599, USA
    J Immunol 186:4518-26. 2011
    ..We conclude that IFN-β-1b exerts its therapeutic effects in part by targeting B cells' functions that contribute to the autoimmune pathogenesis of RR MS...
  54. pmc Immunomodulatory functions of type I interferons
    Jose M Gonzalez-Navajas
    Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0663, USA
    Nat Rev Immunol 12:125-35. 2012
    ..We discuss their function in the regulation of innate and adaptive immune responses, the response to bacterial ligands, inflammasome activation, intestinal homeostasis and inflammatory and autoimmune diseases...
  55. pmc HIV-1 Vpu does not degrade interferon regulatory factor 3
    Dominik Hotter
    Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany
    J Virol 87:7160-5. 2013
    ..Thus, Vpu suppresses innate immune activation through inhibition of NF-κB rather than degradation of IRF-3...
  56. pmc TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1
    Younglang Lee
    Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Korea
    PLoS ONE 8:e63255. 2013
    ..Collectively, our results suggest that TRIM11 inhibits RIG-I-mediated IFNβ production by targeting the TBK1 signaling complex...
  57. ncbi The human fibroblast and human immune interferon genes and their expression in homologous and heterologous cells
    W Fiers
    Philos Trans R Soc Lond B Biol Sci 299:29-38. 1982
    The genetic information coding for human fibroblast interferon (IFN-beta) has been cloned both as a DNA copy (cDNA) and as a genomic clone...
  58. pmc IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA
    Kristi L Peters
    Department of Molecular Biology, The Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Proc Natl Acad Sci U S A 99:6322-7. 2002
    ..Therefore, IRF-3 activation by dsRNA is sufficient to induce the transcription of genes with simple promoters such as 561 as well as complex promoters such as IFN-beta...
  59. ncbi Bovine parainfluenza virus type 3 accessory proteins that suppress beta interferon production
    Takayuki Komatsu
    Microbiology Section, Department of Pathological Sciences, Faculty of Medical Sciences, University of Fukui, 23 3 Shimoaizuki, Matsuoka, Yoshida gun, Fukui 910 1193, Japan
    Microbes Infect 9:954-62. 2007
    ..These results demonstrate that the target of the respirovirus C protein is undoubtedly different from that of the V protein...
  60. pmc Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression
    Eva K Pauli
    Institute of Molecular Virology IMV, Centre of Molecular Biology of Inflammation ZMBE, WWU Muenster, Germany
    PLoS Pathog 4:e1000196. 2008
    ..The inhibitory effect is at least in part due to the induction of SOCS-3 gene expression, which results in an impaired antiviral response...
  61. ncbi Respiratory syncytial virus infection of human respiratory epithelial cells up-regulates class I MHC expression through the induction of IFN-beta and IL-1 alpha
    R Garofalo
    Department of Pediatrics, University of Texas Medical Branch, Galveston 77555, USA
    J Immunol 157:2506-13. 1996
    ....
  62. ncbi IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7
    J Sanceau
    INSERM U 365, Institut Curie, Paris, France
    Oncogene 19:3372-83. 2000
    ....
  63. ncbi Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways
    Keqing Wang
    Medical Research Council Center for Immune Regulation, Birmingham University, Birmingham, United Kingdom
    J Immunol 171:1035-41. 2003
    ..We conclude that type I IFNs inhibit neutrophil apoptosis in a PI3K-dependent manner, which requires activation of protein kinase C-delta and induction of NF-kappaB-regulated genes...
  64. pmc Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression
    Dmitri G Negorev
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19103, USA
    J Virol 80:8019-29. 2006
    ....
  65. ncbi Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report
    C Scoponi
    Department of Oncology, Hospital of Macerata, Italy
    Tumori 81:201-3. 1995
    ..In November 1994, the patient was still in good clinical conditions and disease-free after 37 months from the achievement of complete remission...
  66. ncbi [Contribution of immunology to the treatment of multiple sclerosis]
    J Pérez-Miranda
    Facultad de Medicina, Universidad de Extremadura, Badajoz, Espana
    Rev Neurol 27:117-21. 1998
    ..In this article we review recent advances in understanding the immunological mechanisms involved in the genesis of multiple sclerosis (MS)...
  67. ncbi Natural human interferon-beta in metastatic malignant melanoma. A phase II study
    E A Abdi
    Department of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada
    Acta Oncol 27:815-7. 1988
    A phase II trial of natural human fibroblast interferon (HuIFN-beta) in 15 previously untreated patients with advanced metastatic malignant melanoma is reported. It was given as out-patient treatment by 30 min i.v...
  68. ncbi [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population]
    C Leon
    Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Insurgentes Sur 3877, Colonia La Fama, CP 14269 Ciudad de México, Mexico
    Rev Neurol 31:1019-22. 2000
    ..We present the results of a prospective and a longitudinal study of IFN-beta 1a (Rebif) in the treatment of Mexican patients with relapsing-remittin multiple sclerosis (MS)...
  69. ncbi [Gene transfer of interferon beta inhibits vascular smooth muscle cell proliferation in vitro and in animal model of arterial injury]
    D Stephan
    Institut de Pharmacologie, , Strasbourg
    Arch Mal Coeur Vaiss 90:1121-5. 1997
    ..Gene transfer of an adenoviral vector encoding IFN-beta to VSMC and injured arteries reduced cell proliferation and vascular thickening. This approach is potentially applicable to vascular proliferative diseases...
  70. ncbi Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma
    S Barni
    Divisione di Radioterapia Oncologica, Ospedale San Gerardo, Monza, Milano, Italy
    Tumori 79:343-6. 1993
    ..Further studies in patients with less advanced disease are needed to better define the impact of the immune improvement induced by low-dose IL-2 plus beta-IFN on the clinical course of the neoplastic disease...
  71. ncbi In vitro combined effects of a triazene compound and interferon-beta on natural immunity against lymphoblastoid cells: studies at effector and target cell level
    L Bonmassar
    , Rome, Italy
    Immunopharmacol Immunotoxicol 16:695-715. 1994
    ....
  72. ncbi [Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis]
    J M Gata
    , Hospital Universitario Virgen de la Macarena, Sevilla,
    Rev Neurol 27:939-42. 1998
    INTRODUCTION: We report that interferon beta decreases CD8 T cells percentage and increases CD4/CD8 cell's rate in vivo in Multiple Sclerosis (MS) patients...
  73. ncbi [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial]
    O Fernandez
    Departamento de Neurologia, Hospital Regional De Malaga, Espana
    Rev Neurol 29:1093-9. 1999
    The ability of natural human interferon beta (n-hIFN beta) to reduce multiple sclerosis (MS) activity was investigated in 60 patients with relapsing-remitting MS (RRMS).
  74. ncbi Human interferon-beta, expressed in Saccharomyces cerevisiae, is predominantly directed to the vacuoles. Influence of modified co-expression of secretion factors and chaperones
    J Demolder
    Laboratory of Molecular Biology, Gent University, Belgium
    J Biotechnol 32:179-89. 1994
    ..Only the presence of HSP70 resulted in a 5-fold increase in secreted hIFN-beta...
  75. ncbi Induction of tubuloreticular structures in cultured human endothelial cells by recombinant interferon alfa and beta
    S P Hammar
    Diagnostic Specialties Laboratory, Bremerton, Washington 98310
    Ultrastruct Pathol 16:211-8. 1992
    ..Recombinant interferon beta induced tubuloreticular structures in endothelial cells at a lower concentration and in a greater percentage ..
  76. ncbi Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007
    April M Kunze
    Prime Therapeutics, 1305 Corporate Center Drive, Eagan, MN 55121, USA
    J Manag Care Pharm 13:799-806. 2007
    In 1993, interferon beta-1b became the first of 4 self-injectable multiple sclerosis (MS) drugs to be approved by the U.S. Food and Drug Administration...
  77. doi Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study
    Stephanie C Steinberg
    Accredo Health Group, Inc, The University of Memphis, Memphis, Tennessee, USA
    Clin Drug Investig 30:89-100. 2010
    ..To date, limited evidence exists regarding the effect of patient adherence to interferon-beta therapies on clinical and economic outcomes...
  78. doi The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma
    John B Hamner
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 43:177-82; discussion 182-3. 2008
    ..In this study, we examined the effectiveness of combination therapy of TSA and interferon beta (IFN-beta) on human neuroblastoma cells in vitro and in vivo using a murine model of retroperitoneal ..
  79. doi A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat Edif EUI 2 feminine planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Brain 132:3353-65. 2009
    ....
  80. doi NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 8:519-29. 2009
    Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective, and new more effective and safe strategies are needed...
  81. doi Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study
    Barrie J Hurwitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Ther 30:1102-12. 2008
    It is not known whether the currently available treatment regimen of interferon beta-1b (IFNbeta-1b) 250 microg provides the maximum benefit possible in the treatment of relapsing-remitting multiple sclerosis (RRMS), or whether higher ..
  82. doi Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    Daniel Wynn
    Consultants in Neurology Multiple Sclerosis Center, Northbrook, IL, USA
    Lancet Neurol 9:381-90. 2010
    ..We aimed to assess whether daclizumab reduces disease activity in patients with active relapsing multiple sclerosis who are receiving interferon beta treatment.
  83. ncbi Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C
    Masahiko Kaito
    Third Department of Internal Medicine, Mie University School of Medicine, 2 174 Edobashi, Tsu City, Mie, Japan 514 8507
    Hepatogastroenterology 50:775-8. 2003
    ..We compared the efficacy and safety of twice-a-day versus once-a-day of natural interferon-beta for the initial treatment of patients with chronic hepatitis C...
  84. ncbi Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta
    Anthony Meager
    Division of Immunology and Endocrinology, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts EN6 3QG, UK
    J Immunol Methods 306:1-15. 2005
    Human interferon beta (IFN-beta) has been developed as a major biotherapeutic agent for the treatment of multiple sclerosis...
  85. ncbi Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial
    Qunying Han
    Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi an Jiaotong University, Shaanxi Province, Xi an, China
    Dig Dis Sci 53:2238-45. 2008
    ..To evaluate the efficacy and safety of the interferon beta-1a (IFN beta-1a) versus IFN beta-1a plus ribavirin (RBV) combination on Chinese treatment-naïve patients ..
  86. ncbi A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis
    Daniel R Touchette
    Oregon State University College of Pharmacy, Oregon Health Science University Department of Public Health and Preventive Medicine, Portland, Oregon 97201 3098, USA
    Clin Ther 25:611-34. 2003
    Information on the cost utility of interferon beta-1b and mitoxantrone hydrochloride, 2 disease-modifying agents approved by the US Food and Drug Administration for the treatment of secondary progressive (SP) multiple sclerosis (MS), is ..
  87. pmc Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling
    Ally Khan Somani
    Department of Dermatology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
    Arch Dermatol 144:1341-9. 2008
    ..type I INFs with the production of autoantibodies and the development of certain autoimmune disorders, interferon beta has not previously been described in association with dermatomyositis, to our knowledge...
  88. ncbi Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis
    Paul L McCormack
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:521-46. 2004
    ..The drug is generally well tolerated, and the common adverse events are clinically manageable. Thus, interferon-beta-1b is a valuable first-line therapy for patients with RRMS and a potentially useful option in those with SPMS...
  89. ncbi Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis
    Paul L McCormack
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 18:343-7. 2004
    ..The drug is generally well tolerated, and the common adverse events are clinically manageable. Thus, interferon-beta-1b is a valuable first-line therapy for patients with RRMS and a potentially useful option in those with SPMS...
  90. doi Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 8:987-97. 2009
    ..emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome...
  91. doi Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
    Richard K Burt
    Division of Immunotherapy, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    Lancet Neurol 8:244-53. 2009
    ..We evaluated the safety and clinical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not responded to treatment with interferon beta.
  92. ncbi Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses
    roy W Beck
    CHAMPS Analysis Center, Jaeb Center for Health Research, Tampa, FL 33613, USA
    Ann Neurol 51:481-90. 2002
    The objective of this work was to assess the effect of interferon beta-1a (Avonex) on the rate of development of clinically definite multiple sclerosis and brain magnetic resonance imaging changes in subgroups based on type of presenting ..
  93. ncbi Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
    Ray Gani
    Heron Evidence Development, Letchworth, UK
    Pharmacoeconomics 26:617-27. 2008
    ..These patients are those who experience higher relapse rates and faster disability progression than the general RRMS population...
  94. pmc Regulation of SIV mac 239 basal long terminal repeat activity and viral replication in macrophages: functional roles of two CCAAT/enhancer-binding protein beta sites in activation and interferon beta-mediated suppression
    Shruthi Ravimohan
    McKusick Nathans Institute of Genetic Medicine and Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Biol Chem 285:2258-73. 2010
    ..long terminal repeat (LTR) are crucial for HIV-1 replication in monocyte/macrophages and for the ability of interferon beta (IFN beta) to inhibit ongoing active HIV replication in these cells...
  95. ncbi The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey
    Jason Lundy
    University of Arizona, College of Pharmacy, Tucson, Arizona 85721, USA
    Clin Ther 28:140-5. 2006
    ....
  96. ncbi Interferon-beta gene therapy for cancer: basic research to clinical application
    Jun Yoshida
    Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya 466 8550
    Cancer Sci 95:858-65. 2004
    ..Interferon-beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies...
  97. ncbi Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results
    Frederik Barkhof
    Department of Diagnostic Radiology and Image Analysis Center, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Arch Neurol 64:1292-8. 2007
    In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent ..
  98. doi Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis
    Esther Byun
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0435, USA
    Arch Neurol 65:337-44. 2008
    To identify promising candidate genes linked to interindividual differences in the efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS)...
  99. pmc Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation
    Hong Shen
    Department of Internal Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    BMC Cell Biol 3:9. 2002
    ..Moreover, it is not clear whether there are any differences among interferon alpha, interferon beta, and interferon gamma in the treatment of liver fibrosis...
  100. ncbi Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis
    Peter Rieckmann
    Department of Neurology, Wurzburg, Germany
    Drug Saf 27:745-56. 2004
    ....
  101. ncbi Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis
    Lisa A Prosser
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Value Health 7:554-68. 2004
    To perform a cost-effectiveness analysis of three immunomodulatory treatments for newly diagnosed nonprimary progressive MS: interferon beta-1a, interferon beta-1b, and glatiramer acetate.

Research Grants62

  1. Molecular Stratification of Multiple Sclerosis and Associated Neuro-autoimmune Di
    Robert C Axtell; Fiscal Year: 2012
    ..The major goal of this proposal is to determine the mode of action of IFN-beta therapy and identify biomarkers that can predict responsiveness to this treatment. ..
  2. Robert C Axtell; Fiscal Year: 2015
    ..The proposed research plan, training development and environment at Stanford will be highly conducive for my transition to an independent faculty. ..
  3. Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)
    Fred D Lublin; Fiscal Year: 2012
    ..is a randomized, double blind, placebo controlled, multi-center randomized study of the efficacy of combining interferon beta-la (IFN) and glatiramer acetate (GA) compared to either agent alone as primary therapy for relapsing-..
  4. IFN-BETA CONTROL OF TH CELL DIFFERENTIATION/FUNCTION
    GIJSBERT VAN SEVENTER; Fiscal Year: 2003
    ....
  5. Methamphetamine, Stress and SIV: Effects at Blood-Brain Barrier and Lymph Nodes
    John P Capitanio; Fiscal Year: 2010
    ..Relevance ..
  6. Ratna B Ray; Fiscal Year: 2016
    ..We have recently shown that HCV infection in cell culture activates interferon beta (IFN-2) expression and induces autophagy...
  7. Visualizing Interferon-beta Induction In Vivo
    Joan Durbin; Fiscal Year: 2009
    ..These reagents will allow virologists to study the ability of many different viruses to activate and/or suppress type I IFN production in vivo and in vitro. ..
  8. ERIC KIRK LAU; Fiscal Year: 2014
    ..I have found that PKCepsilon phosphorylated ATF2 represses the expression of Interferon Beta 1 (IFNB1) and related downstream targets...
  9. ATF3-Mediated Transcriptional Repression of Interferon-beta
    STEVE LEE WEINSTEIN; Fiscal Year: 2010
    ..The possibility that repression of IFN-? transcription by ATF-3 is caused by histone deacetylation will be tested by examining the acetylation state of IFN-? promoter histones in the presence or absence of ATF-3 by ChlP. ..
  10. Bone Marrow Stem Cells: Novel Treatment of Human Glioma
    Frederick F Lang; Fiscal Year: 2010
    ....
  11. Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition
    LAWRENCE MARC PFEFFER; Fiscal Year: 2013
    ..In this proposal we plan to pursue a strategy to treat malignant glioma with the potent antitumor cytokine, interferon beta (IFN2).
  12. ACE engineered MSCs as a multidrug-delivery platform for breast cancer therapy
    EDWARD LEON PERKINS; Fiscal Year: 2013
    ..we propose to bioengineer MSCs with an ACE chromosome in order to express, on demand, two anti-tumor factors-interferon beta (IFNb) and the EGFR/MET receptor antagonist decorin (DCN)...
  13. Semaphorin 3F: Structure, Function, and Anti-Metastatic Activity
    Diane Renee Bielenberg; Fiscal Year: 2010
    ..Most of all, a Howard Temin Award would enable the continuation of this research project toward the ultimate goal of long-term stable disease. ..
  14. Peter Mannon; Fiscal Year: 2015
    ..The results will be applicable to other mucosal inflammatory diseases like allergic asthma and eosinophilic esophagitis where IL-13 also drives disease and new therapies targeting IL-13 are needed. ..
  15. INTERFERON RECEPTORS IN ORGAN TRANSPLANTATION
    Verna Gibbs; Fiscal Year: 1999
    ..The information generated from these studies may provide a rational basis for the development of agonists and antagonists which may be clinically useful in preventing acute graft rejection and chronic graft failure. ..
  16. GENE-BASED THERAPIES AND IMAGING OF MALIGNANT GLIOMAS
    Kevin Judy; Fiscal Year: 2003
    ..We believe that this study will have important implications for brain tumor gene therapies in general and provide a new clinical modality for assessing gene transfer. ..
  17. The Effects of Interferons on Anthrax Toxicity
    Andrew Larner; Fiscal Year: 2005
    ..We present evidence that treatment of macrophages with interferon beta (IFNbeta) or interferon gamma (IFNgamma) promotes survival of macrophages after LT exposure...
  18. NOVEL E1 CELL LINE FOR RCA-FREE ADENOVIRAL GENE THERAPY
    Richard Peluso; Fiscal Year: 2001
    ..This cell line will be used to produce adenoviral vectors to deliver INF-beta as an anti-tumor drug and thereby decrease the overall cost of these diseases to the national healthcare system. ..
  19. Rational Optimization of Protein Solubility
    JOHN DESJARLAIS; Fiscal Year: 2003
    ..Protein Design Automation(r) (PDATM), to improve the solubility of an important protein therapeutic, interferon beta. Currently, interferon beta is the primary treatment for multiple sclerosis...
  20. Ebola VP35 mediated viral mechanisms
    Bin He; Fiscal Year: 2004
    ..abstract_text> ..
  21. MRI T2 shortening ('blackT2') in multiple sclerosis
    Rohit Bakshi; Fiscal Year: 2003
    ..Alternatively, if iron accumulation is a disease epiphenomenon, then BT2 could be used as a noninvasive marker of brain degeneration. ..
  22. Treatment of Multiple Sclerosis
    Anthony Reder; Fiscal Year: 2009
    ..of Health Studies and its K30 program, and educate fellows in trial design, statistics, and all neurologic aspects of MS. ..
  23. ACUTE MYOCARDITIS--ROLES OF REOVIRUS AND INTERFERON BETA
    Barbara Sherry; Fiscal Year: 2001
    ..Reoviruses offer a unique tool to investigate the IFN response invoked by closely related viruses in the heart. Our work will be the first to identity cell factors that are determinants of this cardiac IFN response and myocarditis. ..
  24. GROWTH/DIFFERENTIATION FACTORS IN NORMAL/IMMUNE B CELLS
    ROBERT ASHMAN; Fiscal Year: 1992
    ..early biochemical and cell surface events in activation, we will discover whether the differentiation factor interferon beta 2, the high and low molecular weight B cell growth factors, and anti-CDw40, utilize any of the known signal ..
  25. Electroporation-mediated Gene-based Interferon-beta
    Claire Evans; Fiscal Year: 2006
    ..The proposed studies will evaluate the potential of a gene-based interferon-beta therapy for atherosclerosis, and thus will address a very critical need in current medical care. [unreadable] [unreadable] [unreadable]..
  26. Electroporation-Mediated Gene Therapy with IFN-b for MS
    Claire Evans; Fiscal Year: 2005
    ..These studies will set the stage for formal safety/toxicology evaluations and Phase I human studies, with the ultimate goal of providing an effective gene-based IFN-beta therapy for MS. ..
  27. Immunomodulation in Multiple Sclerosis by Interferon B
    Jorge Oksenberg; Fiscal Year: 2005
    ..b>Interferon beta (IFN¿) has been shown to decrease clinical relapses, reduce brain MRI activity, and slow progression of ..
  28. TGF-beta 1-regulated IL-8 expression in prostate cancer
    Zhongyun Dong; Fiscal Year: 2007
    ..TGF-beta1-stimulated IL-8 expression and IL-8 gene promoter activation in cells lacking the three TGF-beta signaling pathways as well as transcription factors involved will be determined. ..
  29. PRDI-BF1 and histone methyltransferase in lymphoma
    Kenneth Wright; Fiscal Year: 2009
    ..Thus this proposal will shed new light on the events occurring during differentiation and may indicate new targets to affect the growth and persistence of lymphomas. ..
  30. Role of interferon beta in hypoxic intestinal epithelium
    Nancy Louis; Fiscal Year: 2006
    Through study of the interaction between interferon beta (IFNbeta) and hypoxia-inducible factor 1 (HIF-1), important advances will be made in understanding epithelial regulation of the exposure of the immune system to contents of the ..
  31. Role of the Fragilis Proteins in the Immune Response
    JOHN WEIS; Fiscal Year: 2005
    The fragilis gene family represents a relatively unknown group of interferon beta inducible genes/gene products who have been implicated in the down modulation of the immune response...
  32. THE ROLE OF IRF PROTEINS IN GENE TRANSCRIPTION
    Aneel Aggarwal; Fiscal Year: 2009
    ..I. PU.1 will be phosphorylated in vitro by casein kinase II prior to crystallization. Together, these aims explore the specificity and cooperativity of these IRFs, and the role of phosphorylation and autoinhibitory elements. ..
  33. Innate Immune Responses in Reovirus Infection
    GEOFFREY HOLM; Fiscal Year: 2007
    ..Together, these studies will provide new insights into the interface between the innate antiviral response, cell death pathways, and viral disease pathogenesis. [unreadable] [unreadable] [unreadable]..
  34. SUSAN ELAINE SWEENEY; Fiscal Year: 2015
    ..sensors recognize viral, bacterial, and endogenous products and induce secretion of type I interferon (IFNa and IFNb) that serve as key sentinel cytokines...
  35. Regulation of AU-rich element-mediated mRNA decay
    Ching Yi Chen; Fiscal Year: 2013
    ..This aim will examine whether Ksrp regulates the decay of Ifna and Ifnb mRNAs and the effect of Ksrp deficiency on virus infection...
  36. Charles S Dela Cruz; Fiscal Year: 2014
    ..Aim 2: Define the role(s) of type I interferons (IFNa, IFNb) and the type 1 IFN pathway in the enhanced inflammatory and remodeling responses induced by CS and RSV...
  37. Epithelial-mesenchymal Transition in the Pathogenesis of Pulmonary Fibrosis
    William E Lawson; Fiscal Year: 2010
    ..Lawson to pursue an independent academic career in pulmonary fibrosis research. In Idiopathic Pulmonary Fibrosis (IFF), progressive parenchymal fibrosis disrupts the structure and gas exchanging functions of the lungs, with ..
  38. Regulation of IFN-beta induction by P2X7 purinergic receptor signaling
    JUDITH ANNE SMITH; Fiscal Year: 2011
    ..to test our underlying hypothesis that P2X7 ligation leads to increased transcription factor occupancy of the ifnb1 promoter...
  39. Gender-Specific Role of Aim2 in Inflammation and Autoimmunity
    Divaker Choubey; Fiscal Year: 2011
    ..stimulates the transcriptional activity of NF-κB in immune cells and suppresses transcription of the Ifnb gene. Genetic, biochemical, and molecular cell biology approaches will be used...
  40. Role of TRIF-dependent TLR signaling in intestinal immunity
    Masayuki Fukata; Fiscal Year: 2011
    ..contrast, the TRIF pathway is only induced by TLR4 or TLR3 and supports regulatory responses through induction of IFNb. Therefore, there must be unique roles of TRIF pathway in intestinal immune regulations, but how this pathway ..
  41. Interferon Regulatory Factors and Periodontal Disease
    Frank C Gibson; Fiscal Year: 2012
    ..Our preliminary data identify increased expression of the ifnb1 gene from wild type macrophages cultured with Pg...
  42. INTERSTITIAL FLUID FLOW IN BONE REMODELING
    John A Frangos; Fiscal Year: 2012
    ..Our objective is to elucidate the mechanisms by which interstitial fluid flow (IFF) stimulates bone cells, using molecular, cell, and in vivo knockout and transgenic models...
  43. Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
    Marxa L Figueiredo; Fiscal Year: 2013
    ....
  44. David A Scott; Fiscal Year: 2016
    ..key role of GSK3b in this signaling cascade, and the mechanisms by which this pathway regulates the expression of IFNb, IL-1Ra, IL-10 in innate cells in addition to controlling T cell development and proliferation...
  45. Osteocyte-independent mechanotransducation of interstitial fluid flow in bone
    Ronald Y Kwon; Fiscal Year: 2010
    A large body of evidence suggests that skeletal interstitial fluid flow (IFF) mediates bone remodeling in response to mechanical loading...
  46. Asymmetric C-C Bond-Forming Reactions Catalyzed by Cinchona Alkaloid Derivatives
    MICHAEL CALTER; Fiscal Year: 2010
    ..an investigation of a series of reactions, all related to one particular reaction, the "interrupted" Feist-Benary (IFB) reaction...
  47. Toll-like Receptors: Novel targets of neuroprotection in ischemic brain injury
    Mary P Stenzel-Poore; Fiscal Year: 2013
    ..Aim 3. Determine whether TNFa and IFNb are critical effectors of ischemic tolerance elicited by TLR9 (CpG) preconditioning. Aim 4...
  48. Pathogen Discovery in Chronic Lung Disease by Mass Tag PCR and Microarray
    W Ian Lipkin; Fiscal Year: 2009
    ..to the pathogenesis of three chronic lung diseases potentially linked to infection: idiopathic pulmonary fibrosis (IFF), pulmonary arterial hypertension (PAH), and bronchiolitis obliterans syndrome (BOS)...
  49. MECHANISM OF INV(16) MEDIATED LEUKEMOGENESIS
    SCOTT HIEBERT; Fiscal Year: 2009
    ..CBFB) to MYH11, which encodes a smooth muscle myosin heavy chain to create the inv(16) fusion grotein (the "IFF")...
  50. Flagellar Motility and Assembly
    George Witman; Fiscal Year: 2006
    ..b>IFF particles from the mouse testis will be isolated and characterized to determine their composition, structure, and ..
  51. Signaling in Cells Chronically Exposed to Interferons
    Andrew Larner; Fiscal Year: 2009
    ..In contrast, in previously de-sensitized cells, IFNB weakly stimulates the assembly of an ISGF3-like complex that lacks tyrosine phosphorylated Stat1, even though ISG54 ..
  52. Electroporation-Mediated Gene Therapy with IFN-b for MS
    MAIDA DE LAS ALAS; Fiscal Year: 2002
    ..TriGrid electroporation (EP) system for in vivo intramuscular delivery of a plasmid encoding for interteron-beta (IFNb) into normal mice...
  53. INTERSTITIAL FLUID FLOW IN BONE REMODELING
    John Frangos; Fiscal Year: 2007
    ..Our objective is to elucidate the mechanisms by which interstitial fluid flow (IFF) stimulates bone cells, using molecular, cell, and in vivo knockout and transgenic models...
  54. Role of IRFs in the Innate Response to HIV
    PAULA PITHA ROWE; Fiscal Year: 2004
    ..translocated to nucleus where they form part of the transcription complex assembled on the promoters of IFNA and IFNB genes...
  55. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  56. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. [unreadable] [unreadable]..
  57. Case/Cleveland Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2004
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  58. Type I Interferon in Innate and Adaptive Virus Immunity
    Curt Horvath; Fiscal Year: 2005
    ..Type I IFNs, IFNA and IFNB, are the principal antiviral cytokines produced by mammalian cells and function directly on target cells by ..
  59. Trypansoma cruzi-induced host cell signaling responses
    Barbara Burleigh; Fiscal Year: 2009
    ..cruzi vacuole formation, maturation and disruption the molecular and cellular levels. Using the induction of IFNb gene expression as a sensitive reporter for host cell transcriptional responses elicited by vacuole egress by T...
  60. Type 1 Interferon in Innate and Adaptive Virus Immunity
    Curt Horvath; Fiscal Year: 2001
    ..Type I IFNs, IFNa and IFNb, are the principle antiviral cytokines produced by mammalian cells and function directly on target cells by ..
  61. Role of Transcription Factor IRF-5 in Infected Cells
    PAULA PITHA ROWE; Fiscal Year: 2001
    ..We have demonstrated also that, while IRF-3 is sufficient for the induction of IFNB genes in infected cells, IRF-7 is a master factor for the induction of IFNAs...